CDC7 serine/threonine kinase inhibitor

oral 50 mg QD, Ph. II in solid tumors compl.

from homology model pharmacophore + opt.

Sci. Adv., May 21, 2021

Takeda Pharmaceutical, Kanagawa, JP

TAK-931

The Takeda CDC7 serine/threonine kinase inhibitor, simurosertib (TAK-931), is the first orally active CDC7-selective inhibitor and recently had its Ph. I study results in solid tumors posted. The drug was…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: